Intratumoral anti-CD47 Immunotherapy
CD47 is a protein that is overexpressed on the surface of many cancer cells, and it interacts with the immune system to inhibit phagocytosis, or the process by which immune cells engulf and destroy cancer cells. This interaction between CD47 and immune cells, including macrophages, can contribute to tumor growth and resistance to immunotherapy.
Intratumoral CD47 blockade is an emerging approach to cancer therapy that involves delivering CD47-blocking agents directly into the tumor site. The goal of this approach is to enhance the phagocytosis of cancer cells by macrophages, thereby reducing tumor growth and enhancing the effectiveness of immunotherapy.
Preclinical studies have shown that intratumoral CD47 blockade can result in tumor regression and improved survival in mouse models of cancer. For example, a study published in the journal Nature in 2016 showed that intratumoral injection of a CD47-blocking antibody enhanced the phagocytosis of cancer cells by macrophages and resulted in the regression of multiple types of tumors, including breast cancer, ovarian cancer, and lymphoma.
Clinical trials evaluating intratumoral CD47 blockade are currently underway in various types of cancer, including solid tumors and hematological malignancies. While the results of these trials are still preliminary, they suggest that intratumoral CD47 blockade has the potential to be an effective cancer therapy, particularly in combination with other immunotherapeutic agents.